ICD-10: C82.80

ICD-10 code C82.80 refers to "Other types of follicular lymphoma, unspecified site." Follicular lymphoma is a type of non-Hodgkin lymphoma (NHL) that arises from B-lymphocytes, specifically from the follicle center cells in lymph nodes. Understanding the clinical presentation, signs, symptoms, and patient characteristics associated with this condition is crucial for diagnosis and management.

Clinical Presentation

Follicular lymphoma typically presents in a manner that can vary significantly among patients. The disease is often indolent, meaning it progresses slowly, and many patients may remain asymptomatic for extended periods. When symptoms do occur, they can include:

• Lymphadenopathy: The most common presentation is painless swelling of lymph nodes, which may be localized or generalized. Patients often notice enlarged lymph nodes in the neck, armpits, or groin.
• Splenomegaly: Enlargement of the spleen can occur, leading to discomfort or a feeling of fullness in the abdomen.
• B Symptoms: Some patients may experience systemic symptoms known as "B symptoms," which include:
• Unexplained fever
• Night sweats
• Unintentional weight loss

Signs and Symptoms

The signs and symptoms of follicular lymphoma can be subtle and may include:

• Painless lymph node enlargement: This is often the first noticeable sign, with nodes that may be rubbery and mobile.
• Fatigue: Patients may report a general sense of tiredness or lack of energy.
• Pruritus: Some patients experience itching, which can be generalized or localized.
• Anemia: As the disease progresses, it may lead to anemia, resulting in symptoms like weakness and pallor.
• Abdominal discomfort: Due to splenomegaly or lymphadenopathy in the abdomen, patients may experience discomfort or fullness.

Patient Characteristics

Certain characteristics may be associated with patients diagnosed with follicular lymphoma:

• Age: Follicular lymphoma is more common in adults, particularly those over the age of 60. The median age at diagnosis is typically around 60-65 years.
• Gender: There is a slight male predominance in the incidence of follicular lymphoma.
• Ethnicity: The condition is more prevalent in Caucasian populations compared to other ethnic groups.
• Family History: A family history of lymphoma or other hematologic malignancies may increase the risk of developing follicular lymphoma.
• Immunocompromised States: Patients with weakened immune systems, such as those with HIV/AIDS or those on immunosuppressive therapy, may have a higher risk of developing lymphomas, including follicular lymphoma.

Conclusion

Follicular lymphoma, classified under ICD-10 code C82.80, presents with a range of clinical features that can vary widely among individuals. The hallmark of this condition is painless lymphadenopathy, often accompanied by systemic symptoms in some patients. Understanding these clinical presentations and patient characteristics is essential for healthcare providers to facilitate timely diagnosis and appropriate management of this indolent form of lymphoma. Regular monitoring and follow-up are crucial, especially in asymptomatic patients, to detect any progression of the disease.

ICD-10 code C82.80 refers to "Other types of follicular lymphoma, unspecified site." This classification falls under the broader category of non-Hodgkin lymphoma (NHL), specifically within the follicular lymphoma subtype. Below is a detailed overview of this condition, including its clinical description, characteristics, and relevant coding information.

Clinical Description of Follicular Lymphoma

What is Follicular Lymphoma?

Follicular lymphoma is a type of non-Hodgkin lymphoma that originates in the lymphatic system, particularly from B-lymphocytes, which are a type of white blood cell. It is characterized by the proliferation of neoplastic follicle center (germinal center) cells. Follicular lymphoma is typically indolent, meaning it tends to grow slowly, but it can transform into a more aggressive form over time.

Characteristics of C82.80

• Unspecified Site: The designation "unspecified site" indicates that the lymphoma may not be localized to a specific anatomical location within the body. This can complicate diagnosis and treatment, as the disease may present in various lymph nodes or extranodal sites without a clear primary site identified.
• Histological Features: Follicular lymphoma is often classified histologically based on the number of centroblasts present in the tissue sample. The most common subtype is follicular lymphoma grade 1, which has a low number of centroblasts, while grade 3 has a higher number and is more aggressive.
• Symptoms: Patients may present with painless lymphadenopathy (swollen lymph nodes), fever, night sweats, weight loss, and fatigue. However, many individuals may be asymptomatic at diagnosis.

Diagnosis and Coding

Diagnostic Criteria

The diagnosis of follicular lymphoma typically involves a combination of clinical evaluation, imaging studies (such as CT scans), and histopathological examination of lymph node biopsies. Immunophenotyping is also crucial, as it helps differentiate follicular lymphoma from other types of lymphomas.

ICD-10 Coding

• ICD-10 Code: C82.80
• Description: Other types of follicular lymphoma, unspecified site
• Related Codes: Other codes in the C82 category include C82.81 (follicular lymphoma, grade 1) and C82.89 (other follicular lymphomas). These codes help specify the type and grade of follicular lymphoma when more information is available.

Treatment Options

Treatment for follicular lymphoma can vary based on the stage of the disease, the patient's overall health, and whether the lymphoma is symptomatic. Common treatment modalities include:

• Watchful Waiting: For asymptomatic patients, especially those with low-grade disease.
• Chemotherapy: Often combined with monoclonal antibodies like rituximab (Rituxan) to enhance efficacy.
• Radiation Therapy: May be used for localized disease.
• Stem Cell Transplantation: Considered for relapsed or refractory cases.

Conclusion

ICD-10 code C82.80 captures a specific category of follicular lymphoma that is not localized to a specific site, reflecting the complexity of this disease. Understanding the clinical characteristics, diagnostic criteria, and treatment options is essential for healthcare providers managing patients with this condition. Accurate coding is crucial for effective communication in clinical settings and for appropriate reimbursement in healthcare systems.

ICD-10 code C82.80 refers to "Other types of follicular lymphoma, unspecified site." Follicular lymphoma is a type of non-Hodgkin lymphoma (NHL) that arises from B-lymphocytes and is characterized by a slow-growing nature. Below are alternative names and related terms associated with this specific ICD-10 code.

Alternative Names for Follicular Lymphoma

1. Follicular Lymphoma, Unspecified: This term is often used interchangeably with C82.80, emphasizing the lack of specification regarding the site of the lymphoma.

2. Non-Hodgkin Follicular Lymphoma: This broader term encompasses all types of follicular lymphoma, including those that are not specified by site.

3. Indolent Follicular Lymphoma: This term highlights the typically slow-growing nature of follicular lymphoma, which is a key characteristic of the disease.

4. Follicular Lymphoma, Grade 1-3: While this classification refers to the histological grading of the lymphoma, it is often associated with the broader category of follicular lymphomas.

Related Terms

1. B-cell Lymphoma: Since follicular lymphoma originates from B-cells, this term is often used in discussions about the disease.

2. Lymphoproliferative Disorders: This term encompasses a range of conditions, including follicular lymphoma, where there is an abnormal proliferation of lymphocytes.

3. Lymphoma: A general term for cancers that originate in the lymphatic system, which includes various types of lymphomas, including follicular lymphoma.

4. Stage IV Lymphoma: In cases where follicular lymphoma has progressed, it may be referred to in the context of staging, although C82.80 itself does not specify a stage.

5. Chronic Lymphocytic Leukemia (CLL): While distinct, CLL can sometimes be confused with follicular lymphoma due to overlapping characteristics in lymphocyte proliferation.

Conclusion

Understanding the alternative names and related terms for ICD-10 code C82.80 is essential for accurate diagnosis, treatment planning, and communication among healthcare professionals. These terms help clarify the nature of the disease and its classification within the broader context of lymphatic neoplasms. If you need further information on treatment options or prognosis related to follicular lymphoma, feel free to ask!

The diagnosis of follicular lymphoma, particularly under the ICD-10 code C82.80, which refers to "Other types of follicular lymphoma, unspecified site," involves a combination of clinical evaluation, laboratory tests, and imaging studies. Below is a detailed overview of the criteria typically used for diagnosing this condition.

Clinical Presentation

Symptoms

Patients with follicular lymphoma may present with a variety of symptoms, including:
- Lymphadenopathy: Swollen lymph nodes, often painless, which can be localized or generalized.
- B-symptoms: These include fever, night sweats, and unexplained weight loss, which may indicate more aggressive disease.
- Fatigue: A common complaint among patients, often due to the disease burden.

Medical History

A thorough medical history is essential, including:
- Previous history of lymphoproliferative disorders.
- Family history of lymphoma or other cancers.
- Any prior treatments that may affect lymphatic tissue.

Laboratory Tests

Blood Tests

• Complete Blood Count (CBC): To assess for anemia, thrombocytopenia, or leukopenia, which can occur in lymphoma.
• Lactate Dehydrogenase (LDH): Elevated levels may indicate a higher tumor burden and correlate with prognosis.

Bone Marrow Biopsy

A bone marrow biopsy may be performed to determine if the lymphoma has spread to the bone marrow, which is common in follicular lymphoma.

Flow Cytometry

Flow cytometry is crucial for identifying the specific characteristics of the lymphoma cells. It helps in confirming the diagnosis by detecting the presence of specific surface markers (e.g., CD10, CD19, CD20, and CD23) that are typically expressed in follicular lymphoma.

Imaging Studies

CT Scans

• Computed Tomography (CT) Scans: These are used to evaluate the extent of lymphadenopathy and to check for any organ involvement.

PET Scans

• Positron Emission Tomography (PET) Scans: Often used in conjunction with CT scans to assess metabolic activity of the lymph nodes and to help stage the disease.

Histopathological Examination

Biopsy

A definitive diagnosis of follicular lymphoma is made through a biopsy of the affected lymph node or tissue. The histopathological examination will reveal:
- Follicular Architecture: The presence of neoplastic follicles.
- Cell Type: Typically, follicular lymphoma is composed of small cleaved cells (centrocytes) and large cells (centroblasts).
- Grading: The grade of the lymphoma (Grade 1, 2, or 3) is determined based on the proportion of centroblasts present.

Genetic Testing

Cytogenetic Analysis

• t(14;18) Translocation: This genetic abnormality is commonly associated with follicular lymphoma and can be detected through cytogenetic analysis or fluorescence in situ hybridization (FISH).

Conclusion

The diagnosis of follicular lymphoma, particularly under the ICD-10 code C82.80, relies on a comprehensive approach that includes clinical evaluation, laboratory tests, imaging studies, and histopathological examination. Each of these components plays a critical role in confirming the diagnosis and determining the appropriate treatment plan. If you have further questions or need more specific information, feel free to ask!

Follicular lymphoma, classified under ICD-10 code C82.80, represents a subtype of non-Hodgkin lymphoma (NHL) characterized by the proliferation of follicle center (germinal center) B-cells. This type of lymphoma is typically indolent, meaning it often progresses slowly, but it can transform into a more aggressive form. The treatment approaches for follicular lymphoma, particularly for unspecified sites, can vary based on several factors, including the stage of the disease, the patient's overall health, and specific characteristics of the lymphoma.

Standard Treatment Approaches

1. Watchful Waiting (Active Surveillance)

For patients with asymptomatic follicular lymphoma, especially those with early-stage disease, a common approach is watchful waiting. This strategy involves regular monitoring without immediate treatment, as many patients may not require intervention for years. This approach is particularly suitable for older patients or those with other significant health issues[1].

2. Chemotherapy

When treatment is necessary, chemotherapy is often the first line of defense. Common regimens include:
- CHOP: Cyclophosphamide, doxorubicin, vincristine, and prednisone.
- R-CHOP: This is a variation that includes rituximab, a monoclonal antibody that targets CD20 on B-cells, enhancing the effectiveness of chemotherapy[2].

3. Immunotherapy

Rituximab is a cornerstone in the treatment of follicular lymphoma. It can be used alone or in combination with chemotherapy. In cases of relapsed or refractory disease, rituximab may be administered as a single agent or in combination with other agents[3]. Newer agents, such as mosunetuzumab (Lunsumio™), are also being explored for their efficacy in treating follicular lymphoma, particularly in patients who have not responded to standard therapies[4].

4. Radioimmunotherapy

This approach combines radiation therapy with immunotherapy. Agents like ibritumomab tiuxetan deliver targeted radiation to lymphoma cells, minimizing damage to surrounding healthy tissue. This method is particularly useful for localized disease or in cases where other treatments have failed[5].

5. Stem Cell Transplantation

For patients with relapsed or refractory follicular lymphoma, high-dose chemotherapy followed by autologous stem cell transplantation may be considered. This approach is typically reserved for younger patients or those with more aggressive disease features[6].

6. Clinical Trials

Participation in clinical trials can provide access to cutting-edge therapies and novel treatment combinations. Patients are encouraged to discuss this option with their healthcare providers, as ongoing research may offer new hope for effective management of their condition[7].

Conclusion

The treatment of follicular lymphoma, particularly for cases coded as C82.80, is multifaceted and tailored to the individual patient. While watchful waiting may be appropriate for some, others may require chemotherapy, immunotherapy, or more advanced treatments like radioimmunotherapy or stem cell transplantation. As research continues to evolve, new therapies and combinations are being explored, offering hope for improved outcomes in this patient population. Patients should engage in thorough discussions with their healthcare teams to determine the most suitable treatment plan based on their specific circumstances.